drugset / Trial / NCT03554031
A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome
Phase 3
Unknown
30 enrolled
Changchun GeneScience Pharmaceutical Co., Ltd.
Beijing Children's Hospital · collabChildren's Hospital of Fudan University · collabHuazhong University of Science and Technology · collabPeking Union Medical College Hospital · collabPeking University First Hospital · collabThe Children's Hospital of Zhejiang University School of Medicine · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the effectiveness of rhGH (Recombinant human growth hormone) injection for improving motor development in patients with PWS.
Timeline
- Start
- 2018-04-14
- Primary completion
- 2020-01
- Completion
- 2020-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Somatropin | Protein / enzyme biologic | 1 mg/m2 | Subcutaneous |